Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02180867 · OUTCOME

Percentage of Patients Who Experienced Grade 3 or Higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery · Source last updated 2026-06-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
Reporting of adverse events was required from the start of protocol therapy and until 30 days from the last administration of study drugs; up to 1 year

What was measured

Participants who experienced Grade 3 or higher toxicity was assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).

Analysis population: Ineligible patients are excluded.

Groups in this outcome

Dose-Finding Level 1 CR

Dose-Finding Level 1 CR: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2

Dose-Finding Level 1 RT

Dose-Finding Level 1 RT: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2

Dose-Finding Level 2 RT

Dose-Finding Level 2 RT: Adult: Pazopanib 800 mg; Pediatric: Pazopanib 450 mg/m2

Regimen A

Regimen A: Chemoradiation plus pazopanib

Regimen B

Regimen B: Chemoradiation alone

Regimen C

Regimen C: Radiation therapy plus pazopanib

Regimen D

Regimen D: Radiation therapy alone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose-Finding Level 1 CR9
Dose-Finding Level 1 RT9
Dose-Finding Level 2 RT10
Regimen A46
Regimen B43
Regimen C6
Regimen D6

Reported measurements

Pediatric Patients

Analysis denominator · Participants

GroupSource count
Dose-Finding Level 1 CR5
Dose-Finding Level 1 RT3
Dose-Finding Level 2 RT3
Regimen A16
Regimen B18
Regimen C1
Regimen D0
Values in Percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Dose-Finding Level 1 CR60Not reported17.06100Not reported
Dose-Finding Level 1 RT66.67Not reported13.32100Not reported
Dose-Finding Level 2 RT33.33Not reported086.68Not reported
Regimen A75Not reported53.7896.22Not reported
Regimen B33.33Not reported11.5655.11Not reported
Regimen C0Not reported00Not reported
Adult Patients

Analysis denominator · Participants

GroupSource count
Dose-Finding Level 1 CR4
Dose-Finding Level 1 RT6
Dose-Finding Level 2 RT7
Regimen A30
Regimen B25
Regimen C5
Regimen D6
Values in Percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Dose-Finding Level 1 CR75Not reported32.56100Not reported
Dose-Finding Level 1 RT66.67Not reported28.95100Not reported
Dose-Finding Level 2 RT57.14Not reported20.4893.80Not reported
Regimen A86.67Not reported74.5098.83Not reported
Regimen B36Not reported17.1854.82Not reported
Regimen C40Not reported082.94Not reported
Regimen D0Not reported00Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        17.06
        upper Limit
        100
        value
        60
      2. group Id
        OG001
        lower Limit
        13.32
        upper Limit
        100
        value
        66.67
      3. group Id
        OG002
        lower Limit
        0
        upper Limit
        86.68
        value
        33.33
      4. group Id
        OG003
        lower Limit
        53.78
        upper Limit
        96.22
        value
        75
      5. group Id
        OG004
        lower Limit
        11.56
        upper Limit
        55.11
        value
        33.33
      6. group Id
        OG005
        lower Limit
        0
        upper Limit
        0
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        5
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        3
      4. group Id
        OG003
        value
        16
      5. group Id
        OG004
        value
        18
      6. group Id
        OG005
        value
        1
      7. group Id
        OG006
        value
        0
      units
      Participants
    title
    Pediatric Patients
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        32.56
        upper Limit
        100
        value
        75
      2. group Id
        OG001
        lower Limit
        28.95
        upper Limit
        100
        value
        66.67
      3. group Id
        OG002
        lower Limit
        20.48
        upper Limit
        93.80
        value
        57.14
      4. group Id
        OG003
        lower Limit
        74.50
        upper Limit
        98.83
        value
        86.67
      5. group Id
        OG004
        lower Limit
        17.18
        upper Limit
        54.82
        value
        36
      6. group Id
        OG005
        lower Limit
        0
        upper Limit
        82.94
        value
        40
      7. group Id
        OG006
        lower Limit
        0
        upper Limit
        0
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      2. group Id
        OG001
        value
        6
      3. group Id
        OG002
        value
        7
      4. group Id
        OG003
        value
        30
      5. group Id
        OG004
        value
        25
      6. group Id
        OG005
        value
        5
      7. group Id
        OG006
        value
        6
      units
      Participants
    title
    Adult Patients
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      9
    3. group Id
      OG002
      value
      10
    4. group Id
      OG003
      value
      46
    5. group Id
      OG004
      value
      43
    6. group Id
      OG005
      value
      6
    7. group Id
      OG006
      value
      6
    units
    Participants
description
Participants who experienced Grade 3 or higher toxicity was assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
dispersion Type
95% Confidence Interval
groups
  1. description
    Dose-Finding Level 1 CR: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2
    id
    OG000
    title
    Dose-Finding Level 1 CR
  2. description
    Dose-Finding Level 1 RT: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2
    id
    OG001
    title
    Dose-Finding Level 1 RT
  3. description
    Dose-Finding Level 2 RT: Adult: Pazopanib 800 mg; Pediatric: Pazopanib 450 mg/m2
    id
    OG002
    title
    Dose-Finding Level 2 RT
  4. description
    Regimen A: Chemoradiation plus pazopanib
    id
    OG003
    title
    Regimen A
  5. description
    Regimen B: Chemoradiation alone
    id
    OG004
    title
    Regimen B
  6. description
    Regimen C: Radiation therapy plus pazopanib
    id
    OG005
    title
    Regimen C
  7. description
    Regimen D: Radiation therapy alone
    id
    OG006
    title
    Regimen D
param Type
NUMBER
population Description
Ineligible patients are excluded.
reporting Status
POSTED
time Frame
Reporting of adverse events was required from the start of protocol therapy and until 30 days from the last administration of study drugs; up to 1 year
title
Percentage of Patients Who Experienced Grade 3 or Higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
type
SECONDARY
unit Of Measure
Percentage of patients

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice